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Abstract Background Poor adherence to inhaled corti-
costeroids (ICS) is known as the main cause for therapeutic
failure in asthma treatment and associated morbidity. To
improve adherence, targetted and effective interventions
need to be developed ideally based on using longitudinal
follow-up of a large study cohort to establish patterns and
influences on adherence. Objective To develop an annual
measure of asthma patients’ adherence to ICS using pri-
mary care prescribing data over consecutive annual inter-
vals, and to statistically model ICS adherence controlling
for a range of patient factors. Setting A retrospective cohort
study between 1997 and 2010 using United Kingdom
general practice prescribing data on asthma patients aged
between 12 and 65 years, without a diagnosis of chronic
obstructive pulmonary disease. Method Patient’s ICS pre-
scriptions are used to calculate the ‘number of days pre-
scribed during calendar year’ divided by ‘number of days
in the interval’ to form an annual prescription possession
ratio (PPR) for each patient. Several definitions of PPR are
considered and compared when calculating numerator and
denominator. Adherence, measured by the preferred PPR,
is then modelled to estimate the effect of asthma exacer-
bation, severity, control and other patient factors on
adherence. Main outcome measure PPR, being a proxy
measure for adherence. Results Annual PPR by all strate-
gies gave a similar frequency profile. ICS were either over-
or under-prescribed for over half of the follow-up time.
Adherence was lower in younger patients, those newer to
the study timeframe, those with less severe asthma, those
with good control, with lower previous adherence, and who
had not previously experienced an exacerbation. Conclu-
sion The chosen PPR simulated clinical use of ICS most
closely; including overlapping days, excess days passed to
the next interval, considering gaps in the denominator, with
censoring at 100 %. The PPR is a useful measure for sig-
nalling or measuring adherence changes over time. The
modelling results identified many characteristics which
would indicate which asthma patients and at what points in
their treatment cycle they would be at increased risk of low
adherence.
Keywords Adherence  Asthma  Exacerbation 
Panel data  Prescription possession ratio
Impact of findings on practice statements
• A method to measure adherence has been developed for
use with ICS in asthma patients, which could be used in
other retrospective adherence studies or in clinical
practice to monitor patients’ adherence.
• Modelling methodology has begun to identify risk
factors that could be used to target asthma patients at
risk of poor adherence to ICS, which could be used to
identify and target efficient and effective interventions
to improve adherence.
Introduction
Medication adherence is commonly defined as: ‘‘the extent
to which a patient acts in accordance with the prescribed
interval and dose of a dosing regimen’’ [1]. Non-adherence
to medicine is associated with reduced health outcomes
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[2–4] and is a notable issue for long-term conditions as
non-adherence rates for long-term therapy typically exceed
50 % [5–7]. A better understanding of the patterns of
change in adherence over time and the factors that may
contribute to poor adherence is especially important in the
management of long term chronic conditions. In order to
elicit these patterns and influences, longitudinal follow-up
and large sample sizes are needed to facilitate the neces-
sary statistical analyses. Outcomes from such work will
contribute to the development of efficient adherence-pro-
moting interventions targeted at the most appropriate times
in a patient’s treatment cycle.
Currently, there is no gold standard measure of adher-
ence. Approaches to measurement include pill counts,
electronic measuring devices, patient log books etc. These
may be suitable in small clinical trials but are impractical
and overly expensive for monitoring medicine use during
routine care, or across large samples of patients. Dispens-
ing data administratively linked to medical records have
been used in some studies [8] but in the UK such data are
not available in sufficiently large samples. Alternately,
patient-level primary care prescribing data can be used to
generate a prescription possession ratio (PPR), defined as
the proportion of the combined number of days prescribed
by individual prescriptions over an annual interval as part
of a patient’s long term treatment. PPR can be considered a
proxy measure for adherence under the assumption that a
patient will fill prescriptions and take the medicine. How-
ever, prescribing frequency and quantity are affected by
both patient attendance at a doctor’s appointment to be able
to receive the prescription (or to request a repeat pre-
scription) and the prescribers choice to write the prescrip-
tion. Despite these limitations, evidence from a New
Zealand study (n = 646) found that adherence estimated
using prescription data was ‘‘a useful predictor of dis-
pensing-based adherence’’ [9].
For asthma management, although the evidence-based
effectiveness of asthma medicines has been proven and
clear prescribing guidelines are available [10, 11], adher-
ence to asthma medicines is known to be low; for example,
Andersson et al. [12] found refill-adherence for asthma
medicines one of the lowest (34 %) when compared to
treatments for other long-term conditions.
In this study, we focussed on inhaled corticosteroids
(ICS) because adherence by asthmatics to these medicines
has been reported to be especially poor [13] and has been
identified as the main cause for failure in asthma treatment
[14] with consequences that include increases in asthma
exacerbations, decreases in patient quality of life [6], and
increases in morbidity, mortality and healthcare costs to the
UK’s National Health Service [15, 16]. The effect of dif-
ferent factors on adherence were considered, including the
age of the patient, control of symptoms, severity of asthma,
and whether the patient had experienced an asthma
exacerbation.
Aim of the study
First, to develop an annual measure of asthma patients’
adherence to ICS by using UK primary care prescribing
data over consecutive annual intervals; and second, to
construct and estimate a patient-level statistical model of
ICS adherence controlling for a range of individual patient
factors.
Methods
Study design and cohort
This retrospective cohort study used data extracted from
the Clinical Practice Research Datalink (CPRD) database
[17]. CPRD is a longitudinal database containing anony-
mised medical records on approximately 12.5 million
acceptable patients (December 2012 build) registered
across 661 general practices located throughout the UK
(April 2013 build). Included in the study were asthma
patients aged between 12 and 65 years whose records in
CPRD fell within the study period 1997–2010 and who
were consented for administrative linkage to their hospital
episode statistics (HES) secondary care inpatient records,
and who were without chronic obstructive pulmonary dis-
ease (COPD). Patients were followed from their respective
index date (when the patient met the inclusion criteria for
entry into the sample frame) up until either: (a) the end date
of the study, or (b) when they reached their 65th birthday,
or (c) were diagnosed with COPD, or (d) died or were
transferred out of their GP practice. Approval for the study
was granted by the Independent Scientific Advisory
Committee of the Medicines and Healthcare products
Regulatory Agency (protocol number 13_036R).
Data management
Included patients’ ICS prescriptions were collected and the
prescribing date and duration (number of days prescribed)
were then used to calculate PPR. Missing values for pre-
scribing duration were imputed by calculating the number
of doses prescribed (quantity of packs multiplied by its
number of doses) divided by the recorded daily prescribed
dose. Errors (such as duplications, swaps, or missing val-
ues) in the number of doses in the pack (pack type) were
checked and any outlying values were corrected based on
pack information taken from the British National Formu-
lary [18]. Missing values for the daily prescribed dose were
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imputed using the patient’s prior prescription records or, if
unavailable, by substitution of the sample median of the
daily prescribed dose by dosage form.
Asthma exacerbation and severity of asthma
Asthma exacerbations were distinguished by whether they
were hospital-recorded (the primary diagnosis ICD-10
coding in HES episode data was J45 or lower) or were
managed in primary care (identification of oral predniso-
lone use to treat exacerbation in the CPRD therapy file). In
addition, keywords (‘‘asthma’’ and ‘‘exacerbation’’,
‘‘emergency prednisolone’’, ‘‘admit to hospital’’, etc) were
matched with relevant Read codes to identify occurrences
of them in the CPRD clinical file, which were then clas-
sified as exacerbation treatment within primary or sec-
ondary care.
To identify oral prednisolone prescribing to treat an
exacerbation, criteria considering the duration (less than
10 days per prescription, less than 90 days per year) and
quantity/dose (qty of less than or equal to 20 and strength is
25 mg, or qty of less than or equal to 112 and strength is
5 mg) were used. Any patient-years with a prednisolone
prescription which failed to meet these criteria were not
considered to be indicative of an exacerbation. Instead,
these patient-years were classified as being treated within
step 5 of the British Thoracic Society and Scottish Inter-
collegiate Guidelines Network (BTS/SIGN) guidelines
[11]. These guidelines are such that a patient’s asthma
severity is increasing in treatment step (ranging from steps
1 to 5) where additional medicines or higher doses are
required to achieve control. A patient presenting at step 1
has their asthma controlled with a short-acting b2-agonist
(SABA) alone, whereas a step 5 patient requires routine
daily prednisolone treatment in order to control their
asthma.
Measuring adherence
In this study, a patient’s adherence to ICS prescriptions was
measured using PPR. This was calculated by dividing
‘number of days prescribed during calendar year’ by
‘number of days in the interval’ and thus was the propor-
tion of days in the year where medicine was prescribed [8].
Expressed as a percentage, it was constructed as follows:
PPR¼ 100Number of days prescribedduring calendar year
Number of days in the interval
Several approaches were considered when evaluating
the numerator, distinguished by whether or not to include
or exclude the overlap in prescription days, and whether to
pass excess prescription days over to the next interval or to
share these proportionally between intervals (see Fig. 1).
The denominator was set to 365 days for an annual
interval, but was adjusted at the beginning or end for when
a patient entered or left the follow-up, or for missing data
in number of doses.
By combining these approaches in differing ways, four
possible strategies were defined for calculating PPR (see
top half of Table 1), of which the first—strategy 1
(including overlapping days, passing excess days to the
next interval, and adjustments to the beginning and end
intervals)—represents the base case. A fifth strategy
imposed a censoring rule on the base case, namely, any
computed value of PPR that exceeded 100 % is reset to
100 %. PPR was calculated for each patient annually
using each strategy (1–5) and the results presented
descriptively.
Modelling adherence
Prescription possession ratio serves as a proxy variable for
adherence (we denote adherence by A and note that it is
unobservable) and so it is subject to error when using it as a
measure of adherence. Let the relationship between these
variables be:
PPR ¼ A þ U
where the unobservable error term U is assumed to have
zero mean. We constructed and estimated inferential
models designed to explain adherence A in terms of its
dynamic behaviour through time as well as to demonstrate
its relationship to clinical outcomes and other factors. In
particular, we use a panel data model to match the study’s
data structure (unbalanced panel data) and consider fixed
effects representations, for example:
PPRit ¼ aPPRi;t1þcYit þb0þb1X1it þþbkXkit þkiþUit
where indexes i ¼ 1; . . .; N patients and t ¼ 1; . . .; T time
periods. The unknown coefficients to be estimated include:
a the coefficient of the lagged dependent variable PPR1
designed to capture any dynamic relationships adherence
may have with itself over time; c the coefficient of Y that
represents clinical outcome and which arguably has a
feedback causal effect with adherence; ðb0; b1; . . .; bkÞ as
the set of k þ 1 coefficients on a set of independent
regressors ð1; X1; X2; . . .; XkÞ where 1 denotes the intercept
and ðX1; X2; . . .; XkÞ are patient-measured attributes (see
Table 2). The patient-specific, arbitrarily distributed indi-
vidual fixed effect is represented by k. The error term
U can be heteroscedastic and autocorrelated. This type of
panel data model has been extensively studied and applied
in numerous studies [19–21]. System generalised method
of moments (system GMM) is an appropriate estimator for
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fixed effects models with a mix of lagged dependent
variables, endogenous and predetermined regressors as
well as strictly exogenous regressors. We implemented this
estimator using Roodman’s xtabond2 algorithm [22] which
is an add-on to the STATA software.
Results
Measuring adherence
Overall, 292,738 patients with 1,181,033 patient-years of
data were included in this study. Descriptive statistics for
each PPR measurement strategy are listed in the top half of
Table 1. By design, strategies 2 and 5 had a maximum
possible PPR value of 100 %, while for those strategies in
which PPR can exceed 100 %, similar extreme ranges were
observed. For the base-case (strategy 1), there were 28.2 %
of patient-years with PPR that exceeded 100 %, while
32.0 % of patient-years had PPR values lower than 50 %.
The proportions of patient-years below 20 % were con-
sistent across all five strategies.
The empirical relative frequency functions of all PPR
measurements are depicted in Fig. 2 for each of strategies
1–4.
Since all of the methods had a similar frequency profile
for PPR, the strategy considered to be the most clinically
appropriate was selected to take forward for modelling
purposes. In clinical practice, patients are unlikely to dis-
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Fig. 1 Calculating the PPR
numerator when prescription
supply overlaps or when the
prescription cuts across the
interval start or end
Table 1 Descriptive statistics
PPR strategya Patient-years
(total = 824,943)
Mean SD Min Max Median
1 A, C, E 822,503 85.45 71.51 0.46 6,135.71 69.86
2 B, C, E 822,503 61.52 27.02 0.36 100 61.92
3 A, D, E 662,797 87.86 67.37 0.36 4,718.52 73.47
4 C, C, F 822,526 80.23 58.28 0.82 1,362.74 66.3
5 Censored strategy 1 at 100 % 822,503 57.56 28.92 0.46 100 69.86
Patient characteristics
Age in years 38.72 15.41 12 65 39
Years in study 3.90 2.96 1 14 3
SABA use 0.04 0.19 0 1 0
BTS/SIGN step 2.70 0.85 2 5 2
Annual change in step 0.02 0.45 -3 3 0
Asthma exacerbations
Annual total 0.29 0.84 0 19 0
Hospital admission 0.01 0.08 0 1 0
Primary care management 0.18 0.38 0 1 0
a A: including overlapping days; B: excluding overlapping day; C: pass excess days to next interval; D: share excess days proportionally
between intervals; E: interval set as 365 days; F: adjusted the beginning and end intervals
Int J Clin Pharm (2014) 36:112–119 115
123
or at the end of a year, especially if the new prescription is
for the same medicine. It is likely that patients will have
gaps in prescribing due to missing data or when newly
entering into, or leaving their registration at their general
practice. Further, once a patient receives enough medicine
to cover every day of the year, they should receive no
additional clinical benefit from any additional doses pre-
scribed. These practices are most closely simulated by
strategy 5, therefore it was this measure which we used to
proxy adherence to ICS and which was subsequently used
for modelling purposes.
Modelling adherence
Using PPR measured using strategy 5, three sets of esti-
mation results are presented in Table 3: for all patients
(column 1) and gender-specific in columns (2) and (3). The
periodicity in the model was annual and as each fitted
model contains 2 prior lags of PPR, only patients recording
data in 3 or more years were included in the estimation
runs; patient numbers are reported under N. Estimates and
associated t-statistics (ratio of estimate to standard error)
are reported. Regression controls were allocated into three
major categories: patient characteristics, persistence and
asthma exacerbations. Baseline values for categorical
variables are indicated by zero coefficients, and so results
can be interpreted relative to a patient who is at BTS/SIGN
treatment step 2 with no high use of SABA in the current
year and who has had no exacerbations of either type in the
prior year. Note that descriptive statistics associated with
the controls were reported earlier in the bottom half of
Table 1.
Table 2 Data definitions
Patient characteristics Description
Age in years The age of the patient in years
Years in study The number of years since the patient first
met the inclusion criteria for the study
SABA use Indicator of asthma control. Prescribing of
over 10 doses per day on average over the
year indicates poor control (1 = patient
has received prescriptions for over 10
SABA per day)
BTS/SIGN step Indicator of asthma severity. The treatment
step taken from the British Guideline on
the Management of Asthma [11]. Patients
treated within steps 2–5 are included in the
study
Annual change in step Indicator for whether a patient has increased
or decreased in severity from their
previous year in the study
Annual total asthma
exacerbations
Number of asthma exacerbations in the year
Hospital admission Asthma exacerbation requiring a hospital
admission (1 = the patient has been




Asthma exacerbation treated within primary
care (1 = the patient has been treated
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Fig. 2 PPR empirical relative
frequency function
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Persistence
The positive, statistically significant estimates of the
coefficients of lagged PPR (PPR-1 is current PPR lagged
by 1 year, and PPR-2 lags it by 2 years) show that the
patient’s history of adherence behaviour has a strong and
reinforcing influence on their current attitude towards ICS
adherence.
Characteristics
Adherence increases with patient age (?0.11 %/year;
t = 37.4) as too it trends positively the longer the patient
remains in contact with the prescriber (years in study:
?0.26 %/year; t = 20.6). High SABA use is indicative of
poor asthma control over a sustained period, when SABA
was used in this manner our estimation results indicated
that adherence to ICS was significantly boosted by
approximately 5 % alongside it (?5.1 %; t = 29.6). As
might be expected adherence worsened as patients were
treated at higher steps in the BTS/SIGN guidelines (step 2
is the base); however, it is important to note the modifi-
cation that should an annual worsening in asthma status
occur (i.e. ‘annual change in step’ = 1 or more), it
prompted the patient to reconsider their adherence behav-
iour and improve it ?2.6 % per increment (t = 31.4). The
flip side to this was that a patient presenting with an annual
improvement in their asthma status (i.e. ‘annual change in
step’ = -1 or lower) was expected to worsen in
adherence.
Exacerbations
The positive estimate (?0.241 %/attack; t = 1.43) implied
that adherence improved as the number of exacerbations
(hospital admit plus managed in primary care; assumed
endogenous) increased, although the estimate did not sig-
nificantly differ from zero. Included into the model and
separated by destination of care were indicators of exacer-
bation occurrence in the previous year; these variables were
Table 3 System GMM estimation results
(1) (2) (3)
All Male Female
Patient count N 97,456 42,740 54,716
Estimate T-stat Estimate T-stat Estimate T-stat
Intercept 24.757 65.02 25.725 41.62 23.892 49.85
Patient characteristics
Age in years 0.110 37.38 0.108 25.24 0.115 28.03
Years in study 0.257 20.56 0.249 12.80 0.264 16.02
SABA use, no = 0 0 0 0
SABA use, yes = 1 5.108 29.55 4.898 20.58 5.380 21.74
BTS/SIGN step 2 0 0 0
BTS/SIGN step 3 -1.472 -13.79 -1.578 -9.96 -1.353 -9.42
BTS/SIGN step 4 -2.513 -20.19 -2.551 -14.66 -2.365 -13.91
BTS/SIGN step 5 -4.014 -8.62 -2.126 -2.81 -4.868 -8.28
Annual change in step 2.595 31.37 2.247 17.60 2.799 25.83
Persistence
PPR-1 0.503 141.89 0.500 88.13 0.507 111.05
PPR-2 0.102 34.82 0.099 21.52 0.103 27.06
Exacerbations
Total in current year 0.241 1.43 0.655 2.71 -0.090 -0.42
Prior year hospital admission, no = 0 0 0 0
Prior year hospital admission, yes = 1 1.653 2.04 2.511 2.11 0.735 0.67
Prior year primary care, no = 1 0 0 0
Prior year primary care, yes = 1 0.942 6.90 1.064 4.71 0.912 5.31
Prior year interaction -0.378 -0.34 -1.024 -0.58 0.989 0.68
Baseline values for categorical variables are indicated with a zero coefficient: being a patient at BTS/SIGN treatment step 2 with no high use of
SABA in the current year and no exacerbations of either type in the prior year
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predetermined. The evidence was now statistically stronger:
patient’s behavioural response to the occurrence of past
exacerbations was to increase their adherence to ICS, where
the ?1.653 % estimate (t = 2.04) of the adherence effect
was greater than ?0.942 % (t = 6.9) than if all prior year
exacerbations were managed solely in primary care.
Gender differences
The differences that emerged when stratifying by gender
focussed mainly on response to exacerbations. As the total
number of current year exacerbations increased males
responded by improving their decision to adhere to ICS
whereas amongst females this was insignificant (males:
?0.655 %/attack; t = 2.71 vs females: -0.09 %/attack;
t = -0.42). Also in evidence is the response to prior year
hospital-treated exacerbation, where the response by males
sees a significant improvement in their current decision to
adhere to ICS (?2.511 %; t = 2.11), whereas amongst
females their response is insignificant (?0.735 %;
t = 0.67).
Discussion
Prescription possession ratio results were not greatly
affected by the method chosen, except for the censoring or
restricting of measures to a maximum of 100 % in strate-
gies 2 and 5. Larger variances were reported for strategies
1, 3 and 4, caused by outliers but mainly by large numbers
of values generated in excess of 100 % (observed to be
28.4 % of patient-years). By censoring these at 100 %, the
mean and variance of PPR must decrease. The presence of
under-prescribing was also highlighted (observed to be
32.1 % of patient-years in which PPR \ 50 %). The clin-
ical reasons for both eventualities, over- and under-pre-
scribing, warrants further investigation. Amongst possible
reasons for over-prescribing may be an absence of under-
standing by the prescriber about what has been prescribed
previously, or by patients receiving but not filling pre-
scriptions. Under-prescribing may be caused by the
patient’s desire to avoid taking the medicine, by the phy-
sician or the patient deeming it to be appropriate despite
not being in line with treatment guidelines [4].
The modelling results reinforce prior expectations that the
better was a patient’s health the lesser was the incentive for
them to adhere to a long-term ICS regimen. On the other
hand, the model showed that when adverse exacerbation
events occurred, patients’ ICS adherence would, at least on
average, be forcibly improved. Moreover, younger age
remained a significant factor detrimental to adherence for
both sexes; for example, the ICS adherence prediction from
the fitted model for a 16 year-old with step 2 disease
averages barely more than 25 %. Admittedly, ‘high’ con-
comitant use of SABA increased the 16 year-olds’ predic-
tion to approximately 30 %, but even so when coupled with
evidence of strong behavioural persistence over time the
young asthmatic was expected to be non-adherent to ICS for
some years, and therefore should arguably be a prime target
for adherence-promoting policy interventions.
Strengths and limitations
Other studies have found PPR to be reflective of the medicine
possession ratio (MPR) [23]; a measure of adherence fre-
quently used in studies using prescription fill data rather than
prescribing data. PPR can be a very useful tool for measuring
adherence using the very rich source of retrospective data
available in the UK, however, it is difficult to interpret the
accuracy of the measure without comparing the adherence
measured by PPR against adherence measured directly; but,
the precision of the method appears to be good. Therefore,
PPR should be used with caution to determine actual levels of
adherence, but if used can be very valuable to measure
changes or differences in adherence over time.
The use of the CPRD prescribing data to calculate adher-
ence, with its large rich source of clinical and patient char-
acteristic data, allows the impact of other patient and clinical
characteristics that may affect adherence to be considered.
However, there are several known limitations of using retro-
spective databases for analysis that would be expected to
affect some of the patient records; including missing or
incorrectly recorded information and incentives giving rise to
record specific types of data and which assign lower priority to
others. Despite these limitations, the large data source allows
the impact on conclusions of these limitations (as long as they
are considered in study design) to be minimal.
There are also many factors that could affect adherence, but
cannot be measured in this setting. Examples of these would be
patient attitudes to their condition or medicine, or the reasons
for the decisions taken by the health care professional to pre-
scribe ICS. The PPR measure uses the assumption that patients
should be prescribed a regular daily dose of ICS to treat their
asthma; however the intention of the health care professional
to prescribe a daily dose is not available. If unobserved het-
erogeneity is integral to the study outcomes, then it would need
to be considered in any modelling of the data and in the
inferences drawn. While the use of fixed effects in modelling
goes some way towards mitigating the deleterious effect of
unobserved heterogeneity, it is still only a partial solution.
Conclusion
An annual measure of asthma patients’ adherence to ICS,
the PPR, measured using CPRD data, was constructed and
118 Int J Clin Pharm (2014) 36:112–119
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found to be a useful measure for signalling, or measuring
adherence changes over time. The chosen PPR methodol-
ogy simulated clinical use of ICS most closely; including
overlapping days, excess days passed to the next interval,
considering gaps in the denominator, with censoring at
100 %. The methods for calculating PPR could be applied
to other chronic conditions; however the method chosen
must be based on knowledge of the specific clinical setting
and disease-medicine characteristics.
A patient-level statistical model of ICS adherence was
constructed, controlling for a range of individual patient
factors. The modelling results identified many character-
istics which would indicate which asthma patients and at
what points in their treatment cycle they would be at
increased risk of low adherence. These risk factors inclu-
ded those with poor adherence in the previous year,
younger patients, higher treatment step, and those patients
who have not recently experienced an exacerbation.
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